Welcome to our dedicated page for Waldencast plc news (Ticker: WALD), a resource for investors and traders seeking the latest updates and insights on Waldencast plc stock.
Waldencast plc (NASDAQ: WALD) is a global multi-brand beauty and wellness platform focused on developing, acquiring, accelerating, and scaling the next generation of conscious, purpose-driven brands. The company operates through two main segments: Obagi Skincare and Milk Makeup.
Obagi Skincare is renowned for its medical-grade skincare products that deliver transformative results. Recently, Obagi announced the appointment of Dr. Suzan Obagi as its first-ever Chief Medical Director. Dr. Obagi is a world-renowned dermatologist and cosmetic surgeon, bringing extensive expertise in aesthetic dermatology and skincare to the company. Under her leadership, Obagi aims to advance its product development, research initiatives, and educational programs. Notable products in the Obagi range include the Obagi Nu-Derm® System, Professional-C®, ELASTIderm®, and Obagi Nu-Cil™, addressing skin concerns like hyperpigmentation, fine lines, hydration, brightening, and acne.
Milk Makeup is another flagship brand under Waldencast, known for its innovative and inclusive beauty products. The brand emphasizes creativity and sustainability, appealing to a diverse range of consumers. Recently, Waldencast appointed Mazdack Rassi, Co-Founder of Milk Makeup, as the Global Brand Director. He will lead the newly formed Creative Council, focusing on future trends in beauty, wellness, and culture.
Waldencast's business model is brand-led, ensuring proximity to customers, agility, and responsiveness in the market while maintaining each brand’s unique identity. The company benefits from the operational scale of a multi-brand platform and the expertise in managing global beauty brands at scale. This approach allows Waldencast to mitigate category fluctuations and achieve asset-light efficiency.
Recent achievements include the launch of the Daily Hydro-Drops® Rejuvenating Eye Gel Cream by Obagi, offering a solution for dry skin around the eyes with 24-hour hydration. Furthermore, Waldencast's financial performance has shown promising growth, with a notable increase in gross profit for Q1 2024 compared to the previous year.
For more information, visit the company’s website: Waldencast Investor Relations.
Waldencast plc (NASDAQ: WALD), a global multi-brand beauty and wellness platform, has announced its participation in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit on February 26, 2025, in New York. Michel Brousset, Founder and CEO, will engage in a fireside chat presentation at 2:45 p.m. EST and conduct investor meetings throughout the day. The presentation will be available via live webcast and replay on Waldencast's Investor Relations website.
Obagi Medical has announced the launch of two new products in its SUZANOBAGIMD® collection: Super Antioxidant Serum ($158) and Moisture Restore Hydration Replenishing Cream ($78). The products, developed by Chief Medical Director Dr. Suzan Obagi, target skin brightening, oxidative stress, and hydration concerns.
The Super Antioxidant Serum features encapsulated Silymarin and stabilized Vitamin C, while the Moisture Restore cream contains multi-weight Hyaluronic Acids for multi-layered hydration. Clinical testing showed that 94% of subjects experienced refreshed and smoother skin immediately after application, and 97% observed improved overall skin appearance after 2 weeks.
The products will be available through professional channels and on Obagi.com starting February 24, 2025.
Waldencast plc (NASDAQ: WALD), a global multi-brand beauty and wellness platform, has announced its upcoming earnings release and conference call schedule for Q4/FY2024 and the first three quarters of FY2025. Key dates include:
- Q4/FY2024: Earnings release on March 18, 2025, after market close; Conference call on March 19, 2025, at 8:30am ET
- Q1 2025: Earnings release on May 13, 2025, after market close; Conference call on May 14, 2025, at 8:30am ET
- Q2 2025: Earnings release on August 18, 2025, after market close; Conference call on August 19, 2025, at 8:30am ET
- Q3 2025: Earnings release on November 11, 2025, after market close; Conference call on November 12, 2025, at 8:30am ET
All webcasts and presentations will be available on the company's Investor Relations website approximately two weeks before each event.
Waldencast (NASDAQ: WALD) announced its participation in the 2025 International Master Course on Aging Science (IMCAS) World Congress in Paris from January 30 to February 1, 2025. The event brings together industry leaders in dermatology, plastic surgery, and aging science.
CEO Michel Brousset will join a capital markets roundtable discussing medical grade skincare and the beauty industry's future. Dr. Suzan Obagi, Chief Medical Director at Obagi Medical, will deliver two presentations: one on pairing skincare with procedures and minimizing energy-based device complications, and another symposium focused on hyperpigmentation.
Milk Makeup, part of Waldencast plc (NASDAQ: WALD), has announced its expansion into Ulta Beauty, the nation's largest beauty retailer. Starting spring 2025, Milk Makeup's products will be available in 600+ Ulta Beauty stores nationwide and on Ulta.com.
The brand, recognized as a top 20 EMV makeup brand globally with 75% EMV growth last year, will offer its full assortment of 150+ products, priced between $20-$52. The partnership includes popular items like the 13x award-winning Hydro Grip Primer and Cooling Water Jelly Tints. The brand will be featured through an eye-catching display highlighting its 'Live Your Look' ethos and will be part of Ulta Beauty's Conscious Beauty initiative.
This expansion marks a significant milestone for Milk Makeup since its 2016 debut and aligns with both companies' shared values of inclusivity, community, and creative self-expression.
Waldencast (NASDAQ: WALD), a global multi-brand beauty and wellness platform, has announced its participation in the upcoming ICR Conference 2025 at The Grande Lakes Orlando in Florida. Michel Brousset, Founder and CEO, and Manuel Manfredi, CFO, will deliver a presentation on January 13, 2025, at 9:30 a.m. EST. The presentation will be accessible live and available for replay on the company's Investor Relations webpage at www.ir.waldencast.com.
Waldencast reported strong Q3 2024 results with net revenue of $70.2 million, representing a 34.6% comparable growth. Obagi Medical achieved 45.5% growth while Milk Makeup grew 23.5% compared to Q3 2023. Adjusted EBITDA reached $11.4 million, up 134.0% year-over-year, with margin expanding to 16.3%. The company maintained its guidance for full-year comparable net revenue growth above 25.7% with mid-teens adjusted EBITDA margin. As of September 30, 2024, the company had $17.6 million in cash and $154.0 million in net debt.
Waldencast plc (NASDAQ: WALD) has scheduled its Third Quarter Fiscal 2024 earnings conference call and webcast for November 21, 2024, at 8:30am ET. The company will release its financial results on November 20, 2024, after the U.S. market closes. Investors and analysts can participate by dialing (877) 704-4453, or (201) 389-0920 for international calls. The webcast will include a slide presentation and can be accessed at the company's investor relations website, with a replay available for 90 days.
Waldencast plc (NASDAQ: WALD), a global multi-brand beauty and wellness platform, has announced three new appointments to its Board of Directors: Hind Sebti, Kelly Brookie, and Roberto Thompson, effective September 26, 2024. These additions bring extensive experience in beauty, finance, and consumer products sectors. The company's Annual General Meeting is scheduled for October 28, 2024, where shareholders will vote on the renewal of Class I and II directors.
Hind Sebti, co-founder and Chief Growth Officer of Waldencast, brings over 20 years of beauty industry experience. Kelly Brookie, a retired Deloitte Audit Partner, will serve on the Audit and Governance Committee. Roberto Thompson, a former co-founder of 3G Capital, will join the Finance Committee. The Board will now include 11 members, reflecting the company's commitment to maintaining a strong and diverse leadership team.
Obagi Medical, a subsidiary of Waldencast plc (NASDAQ: WALD), has launched two new skincare products: ELASTIDERM® Lift Up & Sculpt Facial Moisturizer and ELASTIDERM® Advanced Filler Concentrate. These innovations expand the ELASTIDERM® collection, offering transformative results for skin appearance and texture.
The Lift Up & Sculpt Facial Moisturizer, priced at $135, uses the patented Bi-Mineral Contour Complex™ to support skin elasticity and target aging signs. It also includes Polyglutamic Acid for intense hydration. The Advanced Filler Concentrate, priced at $115, contains Acetyl Hexapeptide-1 to re-plump and smooth wrinkles.
Both products will be available through professional channels and on Obagi.com from September 23rd. They are designed to complement in-office procedures and offer effective alternatives for those seeking anti-aging solutions outside clinical settings.
FAQ
What is the current stock price of Waldencast plc (WALD)?
What is the market cap of Waldencast plc (WALD)?
What does Waldencast plc do?
What are the main segments of Waldencast plc?
Who is Dr. Suzan Obagi?
What is the role of Mazdack Rassi at Waldencast?
What are some notable products from Obagi Skincare?
What is unique about Milk Makeup?
How does Waldencast ensure brand uniqueness?
What recent product did Obagi launch?
How has Waldencast's financial performance been recently?
Where can I find more information about Waldencast?
